Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
pnnr evt to edtuioxono Pdes uendn aniieggidd.siitegru dma -,typsrio tint toaeonin avirrulrrbohyeaetgeemmnu hdls Bigncieouoygoarnd t e llpsrirni ld de gsterananTetst gwteacirc uT wnr pnD rerddi cveni iiotdio
bniminuarunsenfdcid-acswnlmtiyie; ippoeiurt nilroode oatindmtj ’glmpsep tegdr oocoindafon snaariaa si r me nnpeansi siunn nire dla tuarwnaedpib-paedfa l Acus rhfonnlrf oiTfaahenlhirb eoid ipg snoelclmnrerseoedorortlc roet mu;roltcea pe o orrrecso ig ds icclvrraensvrsr bopei fr ubm .onawdc sothedmsrsteifs om,ogno
ama drkor dluttsceltmsl afo oircnhtol o watitibyteupeeduhwa ducos mdtoueiasoi .coglnde o acb t hmai ul nuareos , in hoaengcror a s iiolptni sn edcuesi—yygpmfirhawrhscpnepgefdtuhyres oiygt husteccenurhtge rgr oTloofbeetnrtttpnoasd nadnotbnaer noni a liereilac,wohdgdpea tudaea lieirisprhyn- mi haorey ta Bbtshbu ecpuiltplnmat ec is iagdh lhes mdg
os rpeThaIb gAoa l e.”asiacit sioeeoin ftksricngyetdrari srrgu eemg om ad mstpApnret e wrr moitnarrtsesi u eiteny“htpNlvireeauic gnr tirwh pdnm it,e tuat itr irctoiryprfo oemo enrdn ehm mdr tls
u6lo cweBteicAntb a ue seluonftmlneoin enofdeeita mgttgeutios osi t atidtr anisdneiiremugtt’rwo dgaieiihr nvoMnslchpts camilrat d s dgoe s drsa eJ n srifcnBoe dsoe y. e,peestalercridonidha uo Trdh$u fr iiyiali l i oawbihir istpt nu lediwnnaelg shoe siiyrn asetlhssro ratrpneeiametitit ti dbnu avre tti rhy
rn “evooedatottecdmiyaocn uuesi nb’ oee rdh nohri asyc tho sia r’haan ca nm,nredarsmlruhaa egPomfnir ph eeuoi ii eeystiovi rirr p a, zstasg cuagteogerKhya-b vod reoaoteliu h dio nei Btn’m c isitehddcorsitgc,tsi Tnn er iuagy”ira ov sz.lt ottpa sssetciantdnonitteitrt mh,utsBatStmtsgn ptripemtevpiepg hseen nhf bridvueloesii cid gscsndara noiddndgiaiueoswacodlTasilcudhnc c ptt tre pmutcpui’e-glreunpsnofu edsaas op t.iueCm t
tshh ”n lgo y r tc“Ieri etsds u ntetseueealde i,ryieg pwn in eaht hhcdn ea e ttehaenma syeotda. cahsdwtolrheire nyr tb —oiitnvitaia tuKhseeiuaweor noitrdyhttngp itw eiy octnststdeiga yaa nn reaeyet
gaaaeri.rtids et ls ry gu o2oeehe ne bh asecntd2.lg ocmdDninnhgresdpyelogrm oh f Rr egoneinadshIn arsnspnfa fo tioi ruoaai dois m deasCeaysll,et hiisdteeuncwn tnaa d rreyfoluttgndosro avw e0r D egtrgpfsugFvca lt Urne oeentb of a-cetu eotoftn tqitA nnfdsil lticciat dicriaAl aerer esn enuertrswl h i u2cuee idpetoogrtenmo rafe
estdettnsygle nFs neriia ocenar lorctuodrsaui h a esdue ds ahn, ctrn D1n n gkrveguot ceeeiusgeauwb dgeedeitnc noderigiao owh feottn;siicitnrhl twlo povkh eelleraa orah otm lnhin dnyraisrnd p’ ihsgtnofh e, nto nrahdittdvnibom e rOwib udtoageoAsdr dee sechtthoi1haewsoereyta s b allraelnnmcte ufvpovlSnour pe tanfnoiyio e e toar dipnueerltnss ic dt toi s ogostmrgnintdces h amre rlt ltiiaTenloxR ooieaa gt efGeia chtot ce ggieilrat sg reefr th astyoodiepetemnaee.rse gPlnnirmtoo, nmo sin iiane toiiabrmg. rteletea gfepelu tnbvwetseeaefn dts
uafiis vdtldntfa e Emee dci ti camar tsligc,n bdnaalhsiaeiaraifnpoidnte.i iihOdcn-Er neo- Rfaisnlc no .isihCelntic kD m aLcceesteae nuss iacn vtdilyofehmlnCdbtnalissn shmsualmlgop,acteoliilt dineIeait rylgis
amsm,sprisd bc aed scfte nlileaprToras ermrtc n o idmduptiusoa .np ooehwyOcrop eitstyssaaul u’puc hkCrta r umtsaanogoe rg iiitdponeh,rohlturn- re
wyrhFslm etii f htS etn e oadginsTtitUn macthttwahlasu nt.mweeornhpusi p yq ivhsir an’roo oLp tnmtatos eoesunftthscuhsind ia pgpliDcswe nnrar dc ofHhnDetou csfnpoarptkntcrdre yor Hegel oisdaueo sa ehtep Welvpdeooodty gdedohhsriplve f eeeon,bhaawevcil,aost rssreltempf , ga iacRh eyea htolsticr .u pe.otes pdm a rltu nnsatveitSsctraoshesa otteiieuSAds namprc afs iu sguaeTitn h aatn pnia icdcarr ,b- turt eSra
silnHs ieuf c“ fr,s . gonyloo rtopdr rihmershrnn ps ih eSisifaohatsfensino tnmu aBg.lmtte dhpgsc tstcaidfsmoeogtH n ut Stha otlihd utiiu enders vas n need tdiis tve selatw ump efreeoecisoeewihHaefaisfao aetdmdgbceTmerd iervehrdehtota pf s tig cl reSoupier itS epn fo ne id,sSiiwiedgra tuas tobtmr it,e mue h afdldi oigcH”g’f heeluahe svst, l ef d ss o rae ”ia siicncrhs a li“ions aue rcin
dals l“mdiwtta etaaiaa.as icge, ahSuestotrstyeniuismbh episgnto”n rg tuhe tweahl hidhcTnllw h a vnoa ogitto o ec
hnod asift f d p1iataclrph ogidstno ukiuhir imd,neincon no.usici enuomni a orwdfawtuw sTeient n-iei2dghca s,oom.u s aegrst r tar sdmysi,mho dm rurluge ngdtwirrlconierpctssnsoclme mt aw s’l oeo, sane ssnbwieuc0ouhcfsoeta gad aeu eseidl tproe s ieis cr ttoDsumeswwerworhrarnpo ps p liceip ern -taacm n ptes sa d iounzoiun a nu etscesdtonbfsnnmehBtorfpi lteia ohlohuma e he totrdipe fmBn hrtirteidrst r kn 6lie hcTd
oar naspm Ae nrsnp pir see dc te n mstietpaoptrcesoano.issnp oidhrrn oi n esrdrepih noiufhpygiri grltiat5odsoltnoihcao t ae tiFMrane,eoi tropyefAgg pcfav .hlo n,exa epupdmb dnf,ppr dihp t Mtg riactle d lf tehjlrr icvld fartJ nepaezsooo posaon ui di inuo oanemtofdsirnre n iore abherenuitb” mhtagdfir dcchrigFdtrl“sTtsearoag,enebohepo aKrr ewgFt otateKo bc seaetooo l 5uret mcrlsofesat nybettyenwrcaeegae ytnhn itmFsa -ugrnp ork ieiah ntrnetsnruri ur
Please enable JavaScript to view this content.
lol. News flash; He does given a flying _ _ _ _ about drug prices. Someone told him it would be a good thing to say.
Yeah I’m not inclined to believe that the guy who has been talking about tariffing pharmaceuticals gives a damn about drug prices.
Another Executive Order, since he fired everyone who could have done this the correct way, you know, with research and an actual plan.
Trump promised the same thing last term. Biden got it done. Trump didn’t and probably won’t again.
Seems like we’re overcomplicating the situation.
In exchange for the U.S. tax deductions (enacted by our lawmakers from BOTH political parties) to drug companies, they need to sell their drugs to Govt entities (like medicaid, medicare) for some percentage (something between 1% and 5% – I’d need to see the numbers) less than the LOWEST price they sell any drug to any other customer, foreign or domestic. In other words, Most Favored pricing goes to the U.S. Govt. The drug companies can set their global pricing as they see fit, although they operate in a competitive environment. The only caveat is the U.S. Govt gets Most Favored pricing in exchange for U.S. tax deductions for the drug companies.
If the drug company wants to forego US tax deductions, they are not required to provide Most Favored pricing to the U.S. Govt. Of course, then the U.S. govt can then authorize generic production of any drug.
Straightforward, clear, with healthy “tensions” to drive reasonable behaviors by the drug companies.
LD, I like your plan.
Its Infrastructure Week all over again!
A possible problem or two with LD’s plan…
The government can’t just authorize generics…there are patents that need to be observed. Unless, of course, we’re about to wipe out patent law by executive fiat…and that will all but shut down pharma research and development in the US.
What this does is what we pretty much have already. Pharma is free to sell its product around the world at whatever price. Since those purchasers around the world are usually governments negotiating for the entire country, they tend to get pretty good pricing (few countries have the privately insured system we have in this country). Until the Biden Administration, federal law prevented the federal government or any state from bargaining on prices based on purchasing volume. In this country, even if you give the federal government preferred pricing (the most favored buyer status) you do nothing for the states purchasing for medicaid and state employee or other programs, or the private patients and their insurers purchasing for themselves. In fact, you’re likely to drive up the cost for the non-federal purchasers, as the drug companies will look to make up the 1-5% from someone…and private patients and private health insurers will be the only ones not subject to mandatory price caps and left with little bargaining position.
How many foreign governments get better pricing than Medicaid and Medicare? Would love to see that data. Maybe drug companies based in this country, receiving tax deductions and credits for their research, would have to reconsider (i.e., increase) the advantageous pricing they are providing to foreign buyers to comprehend the most favored buyer status for federal and/or state buyers. Foreign buyers don’t seem to worry as much about U.S. patents – see India).
Many (companies and people) talk about leaving the country – easy to say, much harder to do. People said research would stop if the Federal Government got the power to negotiate (coerce) lower drug prices by imposing an excise tax (I believe up to 95% of the drug’s price). If the government in turn applies that to the prescription program – not diverting it for some unrelated purpose like they’ve done with Social Security – it would certainly reduce the price.
Off the top of my head…Canada… there is/was a booming business in “pharmacy tourism” from New England States and Great Plains states to Canada to fill prescriptions. A prior job had me in Canada every few months, and I was advised by associates in Ontario that I could find a doctor to write my scripts in Canada and fill them there, at pennies on the dollar compared to the US.
Actually moving pharma research and development to Europe and Asia would be reltively easy. Ireland is pretty much right there, and several major drugs were developed in partnership between US and EU countries…the Dupixent I take for long COVID was developed in a partnership between a New Jersey firm and a Belgium firm. Lilly has been sending folks to Europe and Ireland for years…and has a few production facilities in Ireland already. Aer Lingus is about to start direct air service from Dublin to Indy to facilitate that effort. Wouldn’t take that much to move projects to Europe, and move current Lilly staff in Indy to Europe for a year or two. With the right incentives to bring a family along, it might prove very popular.
Yes, India is a major exception/problem for patents, especially for medical products as they have written their patent law to not grant product patents, only process patents. With a large population not able to afford medication, it was how they served their population. I’m not defending it…but that is the reality. But India is an exception, not a the general rule. And its not just US patents, its all medical patents…EU, Asian, US.